846.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly's pre-launch inventories capitalized were $952.3 mln as of September 30 - MarketScreener
Eli Lilly Stock Rises -- Blowout Earnings Smash Forecasts, Lifts 2025 Outlook - Yahoo Finance
Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war - JG-TC.com
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program - Yahoo! Finance Canada
Stock Movers: Meta Falls, Chipotle Plunges, Eli Lilly Jumps - Bloomberg.com
Global markets live: Mastercard, Nvidia, Alphabet, Eli Lilly, Shell… - MarketScreener
ELI LILLY & Co SEC 10-Q Report - TradingView
Lilly hikes revenue forecasts on booming obesity drug sales - BioPharma Dive
Eli Lilly Planning $1.2 Billion Investment in Puerto Rico Manufacturing Site - Pharmaceutical Commerce
Eli Lilly Smashes Views On Back Of Mounjaro, Zepbound - Investor's Business Daily
Eli Lilly exceeds expectations and raises its targets thanks to success of Mounjaro and Zepbound - MarketScreener
Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs - Investopedia
Eli Lilly (LLY) Stock: Q3 Earnings Soar Past Estimates on Weight Loss Drug Sales - parameter.io
Eli Lilly Stock (LLY) Soars as Pharma Giant Raises 2025 Revenue Guidance and Commits $1.2B to Puerto Rico Expansion - Zoom Bangla News
Eli Lilly raises full-year forecast, as weight-loss drugs demand drives third-quarter beat - Yahoo Finance
Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast - Benzinga
Eli Lilly raises forecasts on surging international demand for weight-loss drugs - Reuters
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand - Proactive Investors
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $960 - 富途牛牛
Eli Lilly (LLY) Boosts Profit Forecast Amid Strong Demand for Di - GuruFocus
Lilly Ups Guidance on Weight Loss, Obesity Drugs’ Strength - Bloomberg.com
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000? - ts2.tech
LLY Earnings: Eli Lilly Stock Soars Thanks to Massive Year-Over-Year Growth - TipRanks
Eli Lilly Blows Away Q3 Earnings Expectations - 24/7 Wall St.
Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook - Yahoo Finance
Eli Lilly Stock Rises on Earnings and Boost to Guidance - Barron's
Eli Lilly and Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Eli Lilly and Company (LLY) Stock: Plunge After Q3 2025 Revenue Beat and Upgraded Outlook - CoinCentral
LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings - International Business Times
Eli Lilly Tops Earnings Forecasts and Raises Outlook as Zepbound and Mounjaro Sales Surge - Yahoo Finance
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine - statnews.com
Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates - sharewise.com
Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3 - BioSpace
Eli Lilly stock soars on strong Q3 earnings - Latest news from Azerbaijan
Eli Lilly (LLY) Raises Full-Year Outlook Amid Strong Earnings - GuruFocus
Stocks making the biggest moves premarket: Alphabet, Microsoft, Meta Platforms, Eli Lilly, Merck & more - CNBC
Eli Lilly (LLY) Surges After Beating Q3 Expectations and Raising 2025 Outlook - GuruFocus
Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices - MarketWatch
Eli Lilly and Company (NYSE:LLY) Releases FY 2025 Earnings Guidance - MarketBeat
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill - BioSpace
Eli Lilly’s Weight-Loss Drugs Power Record Revenue Growth - Finimize
Eli Lilly ups full-year profit forecast amid soaring demand for weight-loss drug Zepbound, stock jumps 7% - Mint
Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings - The Wall Street Journal
Lilly earnings soar on growth of Mounjaro, Zepbound - Indianapolis Business Journal
Eli Lilly's (LLY) Q3 Revenue Surpasses Expectations - GuruFocus
Eli Lilly (LLY) Increases Revenue and EPS Guidance for FY25 - GuruFocus
Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand - Investing.com
Lilly: Q3 Earnings Snapshot - San Francisco Chronicle
Alphabet, Eli Lilly and Estee Lauder rise premarket; Meta, Microsoft fall - Investing.com
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion - Pharmaceutical Technology
Eli Lilly Delivers Strong Q3 Performance, Raises Earnings Outlook - Tokenist
Eli Lilly (LLY) Surpasses Q3 Expectations with Strong Earnings - GuruFocus
Eli Lilly raises full-year forecast, sees sustained demand for weight-loss drugs - MarketScreener
New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles - International Business Times
Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally - ts2.tech
Eli Lilly (NYSE:LLY) Delivers Strong Q3 Numbers, Stock Soars - The Globe and Mail
Eli Lilly Raises Outlook on Soaring GLP-1 Demand - The Wall Street Journal
Eli Lilly raises forecasts on surging demand for weight-loss drugs - Yahoo! Finance Canada
Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y - Seeking Alpha
(LLY) Eli Lilly Expects 2025 Revenue Range $63.0B to $63.5B, vs. FactSet Est of $61.74B - MarketScreener
Earnings Flash (LLY) Eli Lilly and Company Reports Q3 Revenue $17.60B, vs. FactSet Est of $16.05B - MarketScreener
Eli Lilly stock pops on raised full-year outlook (LLY:NYSE) - Seeking Alpha
Eli Lilly and : Q3 2025 Lilly Presentation - MarketScreener
Eli Lilly rises after earnings, sales blow past Wall Street’s expectations - Sherwood News
Eli Lilly raises full-year forecast, sees sustained demand for weight-loss drugs By Reuters - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):